Scandion Oncology has finalized the first 12 patients in the CORIST study
Scandion Oncology A/S (“Scandion” or the “Company”) has completed the first 12 patient cohort in the ongoing dose-range finding part of the clinical phase II study with SCO-101 in combination with chemotherapy (FOLFIRI) in patients with drug resistant metastatic colorectal cancer. The Company has now received green light from the Data Safety Monitoring Board to move forward with the next treatment cohorts.In this first cohort from the CORIST study, all patients received combination treatment with SCO-101 and the chemotherapy regime FOLFIRI. The cohort was utilized to stepwise adjust the